
Don't let your healthcare organization's information be compromised. Watch out for these common mistakes.

Don't let your healthcare organization's information be compromised. Watch out for these common mistakes.

Payers weigh the benefits of using their own resources to develop a specialty pharmacy or contracting outside for services.

Innovation will be necessary to compete for consumers in the new market environment. Using data effectively can help plans stand out.

Gilead Sciences, which already makes the leading hepatitis C drugs Harvoni and Sovaldi, recently received priority review from FDA for a new Hepatitis C combination drug.

The Commonwealth Fund examined the effects of the ACA’s Medicaid expansion on low income adults in three states that took different approaches to the law. Here’s what they found.

While forming risk-based entities among Medicaid providers could be an effective way to better manage the care of low-income populations, the risk of unintended consequences cannot be ignored. A key hedge against these consequences is better use of patient data.

After much angst and several delays, the healthcare industry recently completed the ICD-10 transition, but was it really necessary?

Coordination is key in improving adherence and outcomes in patients with chronic conditions. Here’s how.

Amicable resolution between FDA and Pacira Pharmaceuticals, Inc., which reaffirms the broad indication for Exparel (bupivacaine liposome injectable suspension).

Hospital pharmacies need to check their supplies of norepinephrine after PharMEDium Services in Lake Forest, Ill., voluntarily recalled several lots of Norepinephrine Bitartrate. The product is used to control blood pressure in certain acute hypotensive states.

What reimbursement changes can healthcare executives expect in 2016? Three experts weigh in.

Change is in the air as a new year begins. These five trends will continue to gain momentum in the healthcare industry.

There's good news in efforts to combat HIV/AIDs and hepatitis C (hep C, HCV). Some feel, however, that policymakers could do more to prioritize resources to fully eradicate the diseases.

The changing healthcare industry is leading organizations to prioritize new skill sets during recruitment efforts.

Tips to help healthcare executives present their most authentic selves during remote interviews.

The solution to succeeding in value-based reimbursement models is to start inside the hospital with high acuity patients and build the systems that support them.

Optimism exists for biosimilars in the United States, but questions regarding FDA approval and reimbursement remain.

Some providers and payers are hesitant to jump on board with telemedicine, but others say it the benefits are clear.

In late December, FDA approved AstraZeneca’s Zurampic (lesinurad) 200-mg tablets in combination with a xanthine oxidase inhibitor (XOI) for high levels of uric acid in the blood (hyperuricemia) associated with gout.

FDA approved expanded age indication for Human Papillomavirus 9-valent Vaccine, Recombinant (Gardasil 9, Merck) in males.

Survey reveals how size impacts health plan challenges, priorities, outlook, and technology use.

Survey reveals how size impacts hospitals' challenges, priorities, outlook, and technology use.

Here's how more than 600 healthcare executives responded to questions related to reimbursement, pharmaceuticals, consumerism, consolidation, technology, and more.

From changing leadership to new payment models, find out what to expect and how to succeed in 2016.

The FDA recently granted orphan drug approval to Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation.

In the latest controversy over drug pricing, an organization said that the price of GlaxoSmithKline’s Nucala (mepolizumab), an injectable indicated for severe asthma patients with eosinophilic inflammation, is far over-priced.

Sales of Merck’s Keytruda (pembrolizumab) are expected to increase, after FDA approved the drug for first-line treatment of melanoma.

The Association for Community Affiliated Plans recently convened 13 plans to take on together the issue of prescription drug abuse.

FDA approved insulin glargine injection (Basaglar, Eli Lilly) to improve glycemic control in patients with diabetes mellitus.

In this opinion piece, members of the Council for Affordable Health Coverage call for support for the Small Business Healthcare Relief Act.